

To: [redacted]@amsterdamumc.nl [redacted]@amsterdamumc.nl  
From: [redacted]  
Sent: Thur 2/22/2024 8:13:49 AM  
Subject: RE: LymeProspect in aanvraag ZonMw  
Received: Thur 2/22/2024 8:13:49 AM

Hi [redacted]

This is the reference:

[Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study - PubMed \(nih.gov\)](#)

Strong point of this particular study is the availability of pre- and post-infection symptom data, allowing quite accurate correction for background prevalence of symptoms.

Best,  
[redacted]

[redacted]

Center for Infectious Disease Control | Epidemiology and surveillance unit | Department Enteric, Vectorborne and Zoonotic infections (EVZ)  
Dutch National Institute for Public Health and the Environment  
PO Box 1 | 3720 BA Bilthoven  
Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven

T +31 [redacted]  
M +31 [redacted]  
[redacted]@rivm.nl  
<http://www.rivm.nl>

[redacted]

**RIVM** Committed to health and sustainability

---

From: [redacted] <[redacted]@amsterdamumc.nl>  
Sent: woensdag 21 februari 2024 18:45  
To: [redacted] <[redacted]@rivm.nl>  
Subject: Re: LymeProspect in aanvraag ZonMw

Hi [redacted]

Great, thank you!

You commented on the "up to 41%" statistic for post-COVID saying it was closer to 12%. Do you have a reference for this? I included the reference of a review in 2022 for the 41% so want to make sure.

Thanks!

Best,  
[redacted]

[Large redacted area containing multiple instances of [redacted] and some legible text like "Dubbc."]

5.1.2e

5.1.2e

5.1.2e  
5.1.2e  
5.1.2e

5.1.2e

5.1.2e  
5.1.2e

5.1.2e

5.1.2e  
5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

Dubbel

5.1.2e

5.1.2e  
5.1.2e  
5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

Dubbel

5.1.2e

Dubbel